Lung Transplantation for Cystic Fibrosis: Results, Indications, Complications, and Controversies

Abstract

Survival in patients with cystic fibrosis (CF) has improved dramatically over the past 30 to 40 years, with mean survival now approximately 40 years. Nonetheless, progressive respiratory insufficiency remains the major cause of mortality in CF patients, and lung transplantation (LT) is eventually required. Timing of listing for LT is critical, because up to 25 to 41% of CF patients have died while awaiting LT. Globally, approximately 16.4% of lung transplants are performed in adults with CF. Survival rates for LT recipients with CF are superior to other indications, yet LT is associated with substantial morbidity and mortality (∼50% at 5-year survival rates). Myriad complications of LT include allograft failure (acute or chronic), opportunistic infections, and complications of chronic immunosuppressive medications (including malignancy). Determining which patients are candidates for LT is difficult, and survival benefit remains uncertain. In this review, we discuss when LT should be considered, criteria for identifying candidates, contraindications to LT, results post-LT, and specific complications that may be associated with LT. Infectious complications that may complicate CF (particularly Burkholderia cepacia spp., opportunistic fungi, and nontuberculous mycobacteria) are discussed.

Keywords

lung transplant - cystic fibrosis - Burkholderia cepacia spp.

• References

• 1 Quon BS, Aitken ML. Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev 2012; 13 (4) 206-214
• 2 Corris PA. Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2013; 34 (3) 297-304
• 3 Reid DW, Blizzard CL, Shugg DM, Flowers C, Cash C, Greville HM. Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust 2011; 195 (7) 392-395
• 4 Simmonds NJ. Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev 2013; 14 (Suppl. 01) 6-9
• 5 Cystic Fibrosis Foundation Patient Registry. Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD; 2005
• 6 Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29 (3) 522-526
• 7 Adler FR, Aurora P, Barker DH , et al. Lung transplantation for cystic fibrosis. Proc Am Thorac Soc 2009; 6 (8) 619-633
• 8 Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med 2011; 184 (2) 159-171
• 9 Vizza CD, Yusen RD, Lynch JP, Fedele F, Alexander Patterson G, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000; 162 (3, Pt 1): 819-825
• 10 Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant 1993; 12 (4) 669-674
• 11 Ciriaco P, Egan TM, Cairns EL, Thompson JT, Detterbeck FC, Paradowski LJ. Analysis of cystic fibrosis referrals for lung transplantation. Chest 1995; 107 (5) 1323-1327
• 12 Stanchina ML, Tantisira KG, Aquino SL, Wain JC, Ginns LC. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 2002; 21 (2) 217-225
• 13 Yusen RD, Edwards LB, Kucheryavaya AY , et al; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33 (10) 1009-1024
• 14 Lanuza DM, Lefaiver C, Mc Cabe M, Farcas GA, Garrity Jr E. Prospective study of functional status and quality of life before and after lung transplantation. Chest 2000; 118 (1) 115-122
• 15 Durst CL, Horn MV, MacLaughlin EF, Bowman CM, Starnes VA, Woo MS. Psychosocial responses of adolescent cystic fibrosis patients to lung transplantation. Pediatr Transplant 2001; 5 (1) 27-31
• 16 Vermeulen KM, van der Bij W, Erasmus ME, Duiverman EJ, Koëter GH, TenVergert EM. Improved quality of life after lung transplantation in individuals with cystic fibrosis. Pediatr Pulmonol 2004; 37 (5) 419-426
• 17 Kugler C, Strueber M, Tegtbur U, Niedermeyer J, Haverich A. Quality of life 1 year after lung transplantation. Prog Transplant 2004; 14 (4) 331-336
• 18 Yacoub MH, Banner NR, Khaghani A , et al. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation. J Heart Transplant 1990; 9 (5) 459-466 , discussion 466–467
• 19 de Leval MR, Smyth R, Whitehead B , et al. Heart and lung transplantation for terminal cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1991; 101 (4) 633-641 , discussion 641–642
• 20 Vricella LA, Karamichalis JM, Ahmad S, Robbins RC, Whyte RI, Reitz BA. Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience. Ann Thorac Surg 2002; 74 (1) 13-17 , discussion 17–18
• 21 Shennib H, Noirclerc M, Ernst P , et al; The Cystic Fibrosis Transplant Study Group. Double-lung transplantation for cystic fibrosis. Ann Thorac Surg 1992; 54 (1) 27-31 , discussion 31–32
• 22 Ganesh JS, Rogers CA, Bonser RS, Banner NR ; Steering Group of the UK Cardiothoracic Transplant Audit. Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study. Eur Respir J 2005; 25 (6) 964-969
• 23 Egan TM, Detterbeck FC, Mill MR , et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002; 22 (4) 602-609
• 24 Mendeloff EN, Huddleston CB, Mallory GB , et al. Pediatric and adult lung transplantation for cystic fibrosis. J Thorac Cardiovasc Surg 1998; 115 (2) 404-413 , discussion 413–414
• 25 Spahr JE, Love RB, Francois M, Radford K, Meyer KC. Lung transplantation for cystic fibrosis: current concepts and one center's experience. J Cyst Fibros 2007; 6 (5) 334-350
• 26 Samano MN, Pêgo-Fernandes PM, Fonseca Ribeiro AK , et al. Lung transplantation in patients with cystic fibrosis. Transplant Proc 2013; 45 (3) 1137-1141
• 27 Diso D, Anile M, Patella M , et al. Lung transplantation for cystic fibrosis: outcome of 101 single-center consecutive patients. Transplant Proc 2013; 45 (1) 346-348
• 28 Venuta F, Diso D, Anile M , et al. Evolving techniques and perspectives in lung transplantation. Transplant Proc 2005; 37 (6) 2682-2683
• 29 Coloni GF, Venuta F, Ciccone AM , et al. Lung transplantation for cystic fibrosis. Transplant Proc 2004; 36 (3) 648-650
• 30 Starnes VA, Barr ML, Cohen RG , et al. Living-donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg 1996; 112 (5) 1284-1290 , discussion 1290–1291
• 31 Barr ML, Schenkel FA, Cohen RG , et al. Recipient and donor outcomes in living related and unrelated lobar transplantation. Transplant Proc 1998; 30 (5) 2261-2263
• 32 Woo MS, MacLaughlin EF, Horn MV , et al. Living donor lobar lung transplantation: the pediatric experience. Pediatr Transplant 1998; 2 (3) 185-190
• 33 Cohen RG, Barr ML, Schenkel FA, DeMeester TR, Wells WJ, Starnes VA. Living-related donor lobectomy for bilateral lobar transplantation in patients with cystic fibrosis. Ann Thorac Surg 1994; 57 (6) 1423-1427 , discussion 1428
• 34 Starnes VA, Bowdish ME, Woo MS , et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg 2004; 127 (1) 114-122
• 35 Date H, Aoe M, Sano Y , et al. Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 2004; 128 (6) 933-940
• 36 Mitilian D, Sage E, Puyo P , et al; Foch Lung Transplant Group. Techniques and results of lobar lung transplantations. Eur J Cardiothorac Surg 2014; 45 (2) 365-369 , discussion 369–370
• 37 Inci I, Schuurmans MM, Kestenholz P , et al. Long-term outcomes of bilateral lobar lung transplantation. Eur J Cardiothorac Surg 2013; 43 (6) 1220-1225
• 38 Harring TR, Nguyen NT, Liu H, Karpen SJ, Goss JA, O'Mahony CA. Liver transplantation in cystic fibrosis: a report from Baylor College of Medicine and the Texas Children's Hospital. Pediatr Transplant 2013; 17 (3) 271-277
• 39 Van De Wauwer C, Verschuuren EA, Nossent GD , et al. A staged approach for a lung-liver transplant patient using ex vivo reconditioned lungs first followed by an urgent liver transplantation. Transpl Int 2015; 28 (1) 129-133
• 40 Borro JM, Rama P, Rey T, Fernández-Rivera C. Long-term success of combined kidney-lung transplantation in a patient with cystic fibrosis. Arch Bronconeumol 2013; 49 (6) 272-274
• 41 Orens JB, Estenne M, Arcasoy S , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (7) 745-755
• 42 Belkin RA, Henig NR, Singer LG , et al. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2006; 173 (6) 659-666
• 43 Liou TG, Woo MS, Cahill BC. Lung transplantation for cystic fibrosis. Curr Opin Pulm Med 2006; 12 (6) 459-463
• 44 Hirche TO, Knoop C, Hebestreit H , et al; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014; 2014: 621342
• 45 Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18) 1187-1191
• 46 Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004; 126 (2) 412-419
• 47 Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998; 113 (5) 1230-1234
• 48 Augarten A, Akons H, Aviram M , et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001; 5 (5) 339-342
• 49 Venuta F, Rendina EA, De Giacomo T , et al. Timing and priorities for cystic fibrosis patients candidates to lung transplantation. Eur J Pediatr Surg 1998; 8 (5) 274-277
• 50 Venuta F, Rendina EA, Rocca GD , et al. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg 2000; 119 (4, Pt 1): 682-689
• 51 Hayes Jr D, Tobias JD, Mansour HM , et al. Pulmonary hypertension in cystic fibrosis with advanced lung disease. Am J Respir Crit Care Med 2014; 190 (8) 898-905
• 52 Tuppin MP, Paratz JD, Chang AT , et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 2008; 27 (7) 729-734
• 53 Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166 (12, Pt 1): 1550-1555
• 54 Ellaffi M, Vinsonneau C, Coste J , et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171 (2) 158-164
• 55 Hayes Jr D, Higgins RS, Kirkby S , et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. J Cyst Fibros 2014; 13 (4) 416-423
• 56 Flume PA. Pneumothorax in cystic fibrosis. Chest 2003; 123 (1) 217-221
• 57 Smyth RL, Scott JP, McGoldrick JP, Higenbottam TW, Wallwork J. Heart-lung transplantation for pneumothorax in cystic fibrosis. Ann Thorac Surg 1989; 48 (5) 744-745
• 58 Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24 (7) 865-869
• 59 Detterbeck FC, Egan TM, Mill MR. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg 1995; 60 (1) 139-143
• 60 Rolla M, Anile M, Venuta F , et al. Lung transplantation for cystic fibrosis after thoracic surgical procedures. Transplant Proc 2011; 43 (4) 1162-1163
• 61 Dusmet M, Winton TL, Kesten S, Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant 1996; 15 (3) 249-254
• 62 Elizur A, Sweet SC, Huddleston CB , et al. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant 2007; 26 (2) 127-131
• 63 Efrati O, Bylin I, Segal E , et al. Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation?. Heart Lung 2010; 39 (2) 153-159
• 64 Bartz RR, Love RB, Leverson GE, Will LR, Welter DL, Meyer KC. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003; 22 (4) 433-438
• 65 Massard G, Shennib H, Metras D , et al. Double-lung transplantation in mechanically ventilated patients with cystic fibrosis. Ann Thorac Surg 1993; 55 (5) 1087-1091 , discussion 1091–1092
• 66 Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163 (2) 335-338
• 67 Flume PA, Egan TM, Westerman JH , et al. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant 1994; 13 (1, Pt 1): 15-21 , discussion 22–23
• 68 Mason DP, Thuita L, Nowicki ER, Murthy SC, Pettersson GB, Blackstone EH. Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. J Thorac Cardiovasc Surg 2010; 139 (3) 765-773.e1
• 69 Singer JP, Blanc PD, Hoopes C , et al. The impact of pretransplant mechanical ventilation on short- and long-term survival after lung transplantation. Am J Transplant 2011; 11 (10) 2197-2204
• 70 Lang G, Taghavi S, Aigner C , et al. Primary lung transplantation after bridge with extracorporeal membrane oxygenation: a plea for a shift in our paradigms for indications. Transplantation 2012; 93 (7) 729-736
• 71 Casswell GK, Pilcher DV, Martin RS , et al. Buying time: The use of extracorporeal membrane oxygenation as a bridge to lung transplantation in pediatric patients. Pediatr Transplant 2013; 17 (8) E182-E188
• 72 Anile M, Diso D, Russo E , et al. Extracorporeal membrane oxygenation as bridge to lung transplantation. Transplant Proc 2013; 45 (7) 2621-2623
• 73 Lafarge M, Mordant P, Thabut G , et al. Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France. J Heart Lung Transplant 2013; 32 (9) 905-913
• 74 Toyoda Y, Bhama JK, Shigemura N , et al. Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation. J Thorac Cardiovasc Surg 2013; 145 (4) 1065-1070 , discussion 1070–1071
• 75 Garcia JP, Kon ZN, Evans C , et al. Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls. J Thorac Cardiovasc Surg 2011; 142 (4) 755-761
• 76 Fuehner T, Kuehn C, Hadem J , et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012; 185 (7) 763-768
• 77 Olsson KM, Simon A, Strueber M , et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant 2010; 10 (9) 2173-2178
• 78 Schmidt F, Sasse M, Boehne M , et al. Concept of “awake venovenous extracorporeal membrane oxygenation” in pediatric patients awaiting lung transplantation. Pediatr Transplant 2013; 17 (3) 224-230
• 79 Hayes Jr D, Kukreja J, Tobias JD, Ballard HO, Hoopes CW. Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation. J Cyst Fibros 2012; 11 (1) 40-45
• 80 Hayes Jr D, Galantowicz M, Yates AR, Preston TJ, Mansour HM, McConnell PI. Venovenous ECMO as a bridge to lung transplant and a protective strategy for subsequent primary graft dysfunction. J Artif Organs 2013; 16 (3) 382-385
• 81 Kirkby S, Whitson BA, Wehr AM, Lehman AM, Higgins RS, Hayes Jr D. Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients. J Cyst Fibros 2015; 14 (1) 104-110
• 82 Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153 (4) 345-352
• 83 Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005; 171 (9) 1053-1059
• 84 Kirkby S, Hayes Jr D. Pediatric lung transplantation: indications and outcomes. J Thorac Dis 2014; 6 (8) 1024-1031
• 85 Thabut G, Christie JD, Mal H , et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med 2013; 187 (12) 1335-1340
• 86 Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med 2014; 2: 73-82
• 87 Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009; 6 (1) 94-100
• 88 Dorgan DJ, Hadjiliadis D. Lung transplantation in patients with cystic fibrosis: special focus to infection and comorbidities. Expert Rev Respir Med 2014; 8 (3) 315-326
• 89 Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev 2008; 9 (3) 213-219
• 90 Rosbe KW, Jones DT, Rahbar R, Lahiri T, Auerbach AD. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery?. Int J Pediatr Otorhinolaryngol 2001; 61 (2) 113-119
• 91 Mainz JG, Hentschel J, Schien C , et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros 2012; 11 (2) 158-161
• 92 Aanæs K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J Cyst Fibros 2013; 12 (Suppl. 02) S1-S20
• 93 Ciofu O, Johansen HK, Aanaes K , et al. P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. J Cyst Fibros 2013; 12 (6) 729-736
• 94 Mainz JG, Naehrlich L, Schien M , et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax 2009; 64 (6) 535-540
• 95 Holzmann D, Speich R, Kaufmann T , et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation 2004; 77 (1) 134-136
• 96 Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149 (6) 1601-1607
• 97 Kanj SS, Tapson V, Davis RD, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112 (4) 924-930
• 98 Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136 (6) 1554-1560
• 99 Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8 (6) 386-391
• 100 Li Z, Kosorok MR, Farrell PM , et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293 (5) 581-588
• 101 Nunley DR, Grgurich W, Iacono AT , et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998; 113 (5) 1235-1243
• 102 Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant 2007; 26 (9) 890-897
• 103 Walter S, Gudowius P, Bosshammer J , et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 1997; 52 (4) 318-321
• 104 Haja Mydin H, Corris PA, Nicholson A , et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transplant 2012; 2012: 135738
• 105 Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003; 58 (9) 794-796
• 106 Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008; 61 (5) 1057-1061
• 107 Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009; 28 (10) 1275-1279
• 108 Hadjiliadis D, Steele MP, Chaparro C , et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26 (8) 834-838
• 109 Dobbin C, Maley M, Harkness J , et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56 (4) 277-282
• 110 Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155 (5) 1699-1704
• 111 Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162 (6) 2241-2245
• 112 Aaron SD, Vandemheen KL, Ferris W , et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366 (9484) 463-471
• 113 Suhling H, Rademacher J, Greer M , et al. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respir J 2013; 42 (2) 542-544
• 114 Botha P, Archer L, Anderson RL , et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85 (5) 771-774
• 115 Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?. Eur Respir J 2008; 31 (5) 1037-1045
• 116 Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013; 12 (5) 482-486
• 117 Stanojevic S, Ratjen F, Stephens D , et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013; 12 (6) 575-583
• 118 Lynch III JP. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med 2009; 30 (5) 596-610
• 119 LiPuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med 2003; 24 (6) 681-692
• 120 Chaparro C, Maurer J, Gutierrez C , et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163 (1) 43-48
• 121 Alexander BD, Petzold EW, Reller LB , et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8 (5) 1025-1030
• 122 Coenye T, Vandamme P, Govan JR, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39 (10) 3427-3436
• 123 Chen JS, Witzmann KA, Spilker T, Fink RJ, LiPuma JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001; 139 (5) 643-649
• 124 Coenye T, Spilker T, Van Schoor A, LiPuma JJ, Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax 2004; 59 (11) 952-954
• 125 Holden MT, Seth-Smith HM, Crossman LC , et al. The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol 2009; 191 (1) 261-277
• 126 Jones AM, Dodd ME, Govan JR , et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59 (11) 948-951
• 127 Mahenthiralingam E, Vandamme P, Campbell ME , et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33 (9) 1469-1475
• 128 Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164 (11) 2102-2106
• 129 Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178 (4) 363-371
• 130 Frangolias DD, Mahenthiralingam E, Rae S , et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999; 160 (5, Pt 1): 1572-1577
• 131 Manno G, Dalmastri C, Tabacchioni S , et al. Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center. J Clin Microbiol 2004; 42 (4) 1491-1497
• 132 Tablan OC, Martone WJ, Doershuk CF , et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest 1987; 91 (4) 527-532
• 133 Kalish LA, Waltz DA, Dovey M , et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006; 173 (4) 421-425
• 134 Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57 (2) 142-145
• 135 Muhdi K, Edenborough FP, Gumery L , et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996; 51 (4) 374-377
• 136 Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990; 43 (2) 125-131
• 137 De Soyza A, Archer L, Wardle J , et al. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant 2003; 22 (7) 764-769
• 138 Meachery G, De Soyza A, Nicholson A , et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63 (8) 725-731
• 139 De Soyza A, Meachery G, Hester KL , et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29 (12) 1395-1404
• 140 Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103 (2) 466-471
• 141 De Soyza A, McDowell A, Archer L , et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358 (9295) 1780-1781
• 142 Egan JJ, McNeil K, Bookless B , et al. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet 1994; 344 (8921) 552-553
• 143 Savi D, De Biase RV, Amaddeo A , et al. Burkholderia pyrrocinia in cystic fibrosis lung transplantation: a case report. Transplant Proc 2014; 46 (1) 295-297
• 144 de Perrot M, Chaparro C, McRae K , et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg 2004; 127 (5) 1493-1501
• 145 Boussaud V, Guillemain R, Grenet D , et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63 (8) 732-737
• 146 Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161 (4, Pt 1): 1206-1212
• 147 Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007; 51 (3) 1085-1088
• 148 Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37 (1) 123-125
• 149 Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2003; 22 (1) 28-34
• 150 Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009; 33 (5) 394-404
• 151 Tullis DE, Burns JL, Retsch-Bogart GZ , et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014; 13 (3) 296-305
• 152 Woods CW, Bressler AM, LiPuma JJ , et al. Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia. Clin Infect Dis 2004; 38 (9) 1243-1250
• 153 Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol 2008; 104 (6) 1539-1551
• 154 Govan JR, Brown PH, Maddison J , et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342 (8862) 15-19
• 155 Clode FE, Kaufmann ME, Malnick H, Pitt TL. Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol 2000; 38 (5) 1763-1766
• 156 France MW, Dodd ME, Govan JR, Doherty CJ, Webb AK, Jones AM. The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. J Cyst Fibros 2008; 7 (5) 368-372
• 157 Koch C, Frederiksen B, Høiby N. Patient cohorting and infection control. Semin Respir Crit Care Med 2003; 24 (6) 703-716
• 158 McDowell A, Mahenthiralingam E, Dunbar KE, Moore JE, Crowe M, Elborn JS. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol 2004; 53 (Pt 7) 663-668
• 159 Johansen HK, Kovesi TA, Koch C, Corey M, Høiby N, Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol 1998; 26 (2) 89-96
• 160 Saiman L, Macdonald N, Burns JL, Hoiby N, Speert DP, Weber D. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am J Infect Control 2000; 28 (5) 381-385
• 161 Conway S. Segregation is good for patients with cystic fibrosis. J R Soc Med 2008; 101 (Suppl. 01) S31-S35
• 162 Paul ML, Pegler MA, Benn RA. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect 1998; 38 (1) 19-26
• 163 Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008; 22 (2) 89-104
• 164 Nunley DR, Ohori P, Grgurich WF , et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114 (5) 1321-1329
• 165 Liu M, Worley S, Mallory Jr GB , et al. Fungal infections in pediatric lung transplant recipients: colonization and invasive disease. J Heart Lung Transplant 2009; 28 (11) 1226-1230
• 166 Iversen M, Burton CM, Vand S , et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26 (12) 879-886
• 167 Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22 (3) 258-266
• 168 Cahill BC, Hibbs JR, Savik K , et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112 (5) 1160-1164
• 169 Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch III JP. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001; 119 (1) 169-175
• 170 Minari A, Husni R, Avery RK , et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4 (4) 195-200
• 171 Solé A, Morant P, Salavert M, Pemán J, Morales P. Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11 (5) 359-365
• 172 Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78 (2) 123-138
• 173 Liu JC, Modha DE, Gaillard EA. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis?. J Cyst Fibros 2013; 12 (3) 187-193
• 174 Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123 (3) 800-808
• 175 Luong ML, Chaparro C, Stephenson A , et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97 (3) 351-357
• 176 de Vrankrijker AM, van der Ent CK, van Berkhout FT , et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?. Clin Microbiol Infect 2011; 17 (9) 1381-1386
• 177 Egan JJ, Yonan N, Carroll KB, Deiraniya AK, Webb AK, Woodcock AA. Allergic bronchopulmonary aspergillosis in lung allograft recipients. Eur Respir J 1996; 9 (1) 169-171
• 178 Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45 (8) 764-771
• 179 Paugam A, Baixench MT, Demazes-Dufeu N , et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 (Suppl. 01) S32-S36
• 180 Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130 (1) 222-226
• 181 Pappas PG, Alexander BD, Andes DR , et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8) 1101-1111
• 182 Bhaskaran A, Hosseini-Moghaddam SM, Rotstein C, Husain S. Mold infections in lung transplant recipients. Semin Respir Crit Care Med 2013; 34 (3) 371-379
• 183 Husni RN, Gordon SM, Longworth DL , et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3) 753-755
• 184 Husain S, Paterson DL, Studer S , et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6 (12) 3008-3016
• 185 Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61 (6) 915-919
• 186 Goldfarb NS, Avery RK, Goormastic M , et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71 (2) 242-246
• 187 Mead L, Danziger-Isakov LA, Michaels MG, Goldfarb S, Glanville AR, Benden C ; International Pediatric Lung Transplant Collaborative (IPLTC). Antifungal prophylaxis in pediatric lung transplantation: an international multicenter survey. Pediatr Transplant 2014; 18 (4) 393-397
• 188 Avery RK. Antifungal prophylaxis in lung transplantation. Semin Respir Crit Care Med 2011; 32 (6) 717-726
• 189 Kramer MR, Denning DW, Marshall SE , et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991; 144 (3, Pt 1) 552-556
• 190 Wu N, Huang Y, Li Q, Bai C, Huang HD, Yao XP. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect 2010; 16 (6) 689-695
• 191 Nunley DR, Gal AA, Vega JD, Perlino C, Smith P, Lawrence EC. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002; 122 (4) 1185-1191
• 192 Fernández-Ruiz M, Silva JT, San-Juan R , et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91 (5) 261-273
• 193 Neofytos D, Fishman JA, Horn D , et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (3) 220-229
• 194 Pihet M, Carrere J, Cimon B , et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. Med Mycol 2009; 47 (4) 387-397
• 195 Park SY, Kim SH, Choi SH , et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis 2010; 12 (4) 309-315
• 196 Husain S, Kwak EJ, Obman A , et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4 (5) 796-802
• 197 Husain S, Paterson DL, Studer SM , et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83 (10) 1330-1336
• 198 Luong ML, Clancy CJ, Vadnerkar A , et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52 (10) 1218-1226
• 199 Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest 2002; 121 (1) 128-134
• 200 Billaud EM, Guillemain R, Berge M , et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010; 48 (Suppl. 01) S52-S59
• 201 Han K, Capitano B, Bies R , et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54 (10) 4424-4431
• 202 Thompson III GR, Patterson TF. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med 2011; 32 (6) 673-681
• 203 Baddley JW, Andes DR, Marr KA , et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50 (12) 1559-1567
• 204 Steinbach WJ, Marr KA, Anaissie EJ , et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65 (5) 453-464
• 205 Herbrecht R, Denning DW, Patterson TF , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) 408-415
• 206 Singh N, Limaye AP, Forrest G , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (3) 320-326
• 207 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
• 208 Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (Suppl. 03) S157-S187
• 209 Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit 2012; 34 (1) 77-84
• 210 Brett J, Chong O, Graham GG , et al. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther Drug Monit 2013; 35 (1) 133-136
• 211 Mitsani D, Nguyen MH, Shields RK , et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56 (5) 2371-2377
• 212 Viscoli C, Herbrecht R, Akan H , et al; Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64 (6) 1274-1281
• 213 Hiemenz JW, Raad II, Maertens JA , et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010; 29 (11) 1387-1394
• 214 Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive Aspergillus disease, a retrospective analysis. Mycoses 2013; 56 (3) 304-310
• 215 Ullmann AJ, Lipton JH, Vesole DH , et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4) 335-347
• 216 Cornely OA, Maertens J, Winston DJ , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4) 348-359
• 217 Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?. Cancer 2010; 116 (22) 5290-5296
• 218 Weigt SS, Elashoff RM, Huang C , et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9 (8) 1903-1911
• 219 Weigt SS, Copeland CA, Derhovanessian A , et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant 2013; 13 (4) 919-927
• 220 Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006; 8 (4) 213-218
• 221 Neoh CF, Snell GI, Kotsimbos T , et al. Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant 2011; 11 (2) 361-366
• 222 Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients?. Curr Opin Infect Dis 2013; 26 (4) 317-325
• 223 Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012; 44 (11) 835-841
• 224 Reichenspurner H, Gamberg P, Nitschke M , et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29 (1-2) 627-628
• 225 Drew RH, Dodds Ashley E, Benjamin Jr DK, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77 (2) 232-237
• 226 Monforte V, Ussetti P, Gavaldà J , et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29 (5) 523-530
• 227 Cadena J, Levine DJ, Angel LF , et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9 (9) 2085-2091
• 228 Lowry CM, Marty FM, Vargas SO , et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007; 9 (2) 121-125
• 229 Eriksson M, Lemström K, Suojaranta-Ylinen R , et al. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. Transplant Proc 2010; 42 (10) 4459-4464
• 230 Koo S, Kubiak DW, Issa NC , et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation 2012; 94 (3) 281-286
• 231 Singh N, Husain S ; AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 228-241
• 232 Zwald FO, Spratt M, Lemos BD , et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38 (8) 1369-1374
• 233 Vadnerkar A, Nguyen MH, Mitsani D , et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29 (11) 1240-1244
• 234 Singer JP, Boker A, Metchnikoff C , et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31 (7) 694-699
• 235 Palmer SM, Perfect JR, Howell DN , et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998; 17 (10) 1029-1033
• 236 Hadjiliadis D, Howell DN, Davis RD , et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000; 5 (3) 13-19
• 237 Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6 (10) 2365-2374
• 238 Neofytos D, Treadway S, Ostrander D , et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15 (3) 233-242
• 239 Quan C, Spellberg B. Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc 2010; 7 (3) 210-215
• 240 Neto FM, Camargo PC, Costa AN , et al. Fungal infection by Mucorales order in lung transplantation: 4 case reports. Transplant Proc 2014; 46 (6) 1849-1851
• 241 Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23 (12) 1451-1454
• 242 Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32 (8) 1237-1240
• 243 Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis 2001; 3 (4) 189-194
• 244 Musk M, Chambers D, Chin W, Murray R, Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 2006; 25 (10) 1268-1272
• 245 Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 2002; 121 (5) 1714-1716
• 246 Symoens F, Knoop C, Schrooyen M , et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant 2006; 25 (5) 603-607
• 247 Morio F, Horeau-Langlard D, Gay-Andrieu F , et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol 2010; 48 (5) 1978-1982
• 248 Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002; 81 (5) 333-348
• 249 Cimon B, Carrère J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19 (1) 53-56
• 250 Hartmann C, Müller C, Weißbrodt H , et al. Successful prevention of scedosporiosis after lung transplantation in a cystic fibrosis patient by combined local and systemic triazole therapy. Med Mycol Case Rep 2013; 2: 116-118
• 251 Russell GK, Gadhok R, Simmonds NJ. The destructive combination of Scediosporium apiosperum lung disease and exuberant inflammation in cystic fibrosis. Paediatr Respir Rev 2013; 14 (Suppl. 01) 22-25
• 252 Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32 (6) 693-702
• 253 Cavusoglu C, Cicek-Saydam C, Karasu Z , et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant 2002; 16 (4) 257-261
• 254 Shitrit D, Bendayan D, Saute M, Kramer MR. Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection. Thorax 2004; 59 (1) 79-80
• 255 Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160 (5, Pt 1): 1611-1616
• 256 Lee J, Yew WW, Wong CF, Wong PC, Chiu CS. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003; 22 (10) 1168-1173
• 257 Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27 (5) 1266-1277
• 258 Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40 (4) 581-587
• 259 Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152 (1) 374-376
• 260 Aguilar-Guisado M, Givaldá J, Ussetti P , et al; RESITRA cohort. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007; 7 (8) 1989-1996
• 261 Olivier KN, Weber DJ, Lee JH , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167 (6) 835-840
• 262 Olivier KN, Weber DJ, Wallace Jr RJ , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167 (6) 828-834
• 263 Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34 (1) 124-134
• 264 Oliver A, Maiz L, Cantón R, Escobar H, Baquero F, Gómez-Mampaso E. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001; 32 (9) 1298-1303
• 265 Razvi S, Saiman L. Nontuberculous mycobacteria in cystic fibrosis. Pediatr Infect Dis J 2007; 26 (3) 263-264
• 266 Levy I, Grisaru-Soen G, Lerner-Geva L , et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14 (3) 378-384
• 267 Bar-On O, Mussaffi H, Mei-Zahav M , et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros 2015; 14 (1) 53-62
• 268 Qvist T, Gilljam M, Jonsson B , et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015; 14 (1) 46-52
• 269 Chernenko SM, Humar A, Hutcheon M , et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25 (12) 1447-1455
• 270 Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115 (3) 741-745
• 271 Chalermskulrat W, Sood N, Neuringer IP , et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61 (6) 507-513
• 272 Huang HC, Weigt SS, Derhovanessian A , et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30 (7) 790-798
• 273 Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C , et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003; 9 (12) 1587-1591
• 274 Roux AL, Catherinot E, Ripoll F , et al; Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47 (12) 4124-4128
• 275 Hjelte L, Petrini B, Källenius G, Strandvik B. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990; 45 (5) 397-400
• 276 Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med 2009; 30 (5) 539-546
• 277 Efthimiou J, Smith MJ, Hodson ME, Batten JC. Fatal pulmonary infection with Mycobacterium fortuitum in cystic fibrosis. Br J Dis Chest 1984; 78 (3) 299-302
• 278 Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002; 21 (3) 391-394
• 279 Sanguinetti M, Ardito F, Fiscarelli E , et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39 (2) 816-819
• 280 Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38 (10) 1428-1439
• 281 Torres F, Hodges T, Zamora MR. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant 2001; 20 (4) 486-489
• 282 Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25 (8) 985-988
• 283 Muñoz RM, Alonso-Pulpón L, Yebra M, Segovia J, Gallego JC, Daza RM. Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis 2000; 30 (3) 603-605
• 284 Griffith DE, Aksamit T, Brown-Elliott BA , et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 (4) 367-416
• 285 Sugihara E, Hirota N, Niizeki T , et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother 2003; 9 (4) 328-332
• 286 Koh WJ, Lee KS, Kwon OJ, Jeong YJ, Kwak SH, Kim TS. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005; 235 (1) 282-288
• 287 Ellis SM. The spectrum of tuberculosis and non-tuberculous mycobacterial infection. Eur Radiol 2004; 14 (Suppl. 03) E34-E42
• 288 Trulock EP, Bolman RM, Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis 1989; 140 (3) 802-805
• 289 Baldi S, Rapellino M, Ruffini E, Cavallo A, Mancuso M. Atypical mycobacteriosis in a lung transplant recipient. Eur Respir J 1997; 10 (4) 952-954
• 290 Gilljam M, Scherstén H, Silverborn M, Jönsson B, Ericsson Hollsing A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010; 9 (4) 272-276
• 291 Robinson PD, Harris KA, Aurora P, Hartley JC, Tsang V, Spencer H. Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species. Eur Respir J 2013; 41 (5) 1230-1232
• 292 Aitken ML, Limaye A, Pottinger P , et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185 (2) 231-232
• 293 Knoll BM, Kappagoda S, Gill RR , et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14 (5) 452-460
• 294 Zaidi S, Elidemir O, Heinle JS , et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11 (3) 243-248
• 295 Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012; 25 (2) 218-227
• 296 Colin AA. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000; 30 (3) 267-268
• 297 Radhakrishnan DK, Yau Y, Corey M , et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009; 44 (11) 1100-1106
• 298 Saiman L, Siegel J ; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31 (3, Suppl): S1-S62
• 299 Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013; 34 (1) 87-94
• 300 Bange FC, Brown BA, Smaczny C, Wallace Jr RJ, Böttger EC. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001; 32 (11) 1648-1650
• 301 Bryant JM, Grogono DM, Greaves D , et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381 (9877) 1551-1560
• 302 Davidson RM, Reynolds PR, Farias-Hesson E, Duarte RS, Jackson M, Strong M. Genome Sequence of an Epidemic Isolate of Mycobacterium abscessus subsp. bolletii from Rio de Janeiro, Brazil. Genome announcements 2013; 1
• 303 Tettelin H, Davidson RM, Agrawal S , et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis 2014; 20 (3) 364-371
• 304 Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27 (1) 11-16
• 305 Clark NM, Lynch III JP, Sayah D, Belperio JA, Fishbein MC, Weigt SS. DNA viral infections complicating lung transplantation. Semin Respir Crit Care Med 2013; 34 (3) 380-404
• 306 Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007; 26 (1) 41-47
• 307 Weigt SS, Gregson AL, Deng JC, Lynch III JP, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011; 32 (4) 471-493
• 308 Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33 (2) 311-316
• 309 Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32 (9) 1626-1631
• 310 Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28 (9) 2141-2144
• 311 Moran A, Brunzell C, Cohen RC , et al; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33 (12) 2697-2708
• 312 Hadjiliadis D, Madill J, Chaparro C , et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant 2005; 19 (6) 773-778
• 313 Hofer M, Schmid C, Benden C , et al. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibros 2012; 11 (2) 131-136
• 314 Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4 (4) 583-595
• 315 Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996; 109 (5) 1176-1183
• 316 Donovan Jr DS, Papadopoulos A, Staron RB , et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 1998; 157 (6, Pt 1) 1892-1899
• 317 Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation 2001; 72 (7) 1251-1255
• 318 Legroux-Gérot I, Leroy S, Prudhomme C , et al. Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. Joint Bone Spine 2012; 79 (1) 73-77
• 319 Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 2014;
• 320 Hecker TM, Aris RM. Management of osteoporosis in adults with cystic fibrosis. Drugs 2004; 64 (2) 133-147
• 321 Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117 (2) 476-481
• 322 Aris RM, Renner JB, Winders AD , et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128 (3) 186-193
• 323 Aris RM, Lester GE, Renner JB , et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000; 162 (3, Pt 1) 941-946
• 324 Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014; 3: CD002010
• 325 Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol 2013; 11 (4) 333-342 , quiz e30–e31
• 326 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013; 19 (6) 676-680
• 327 Shah N, Tan HL, Sebire N, Suri R, Leuven K. The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients. Pediatr Pulmonol 2013; 48 (12) 1181-1189
• 328 Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol 2012; 107 (9) 1346-1353
• 329 Gilljam M, Chaparro C, Tullis E, Chan C, Keshavjee S, Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003; 123 (1) 37-41
• 330 Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124 (5) 1689-1693
• 331 Lubetkin EI, Lipson DA, Palevsky HI , et al. GI complications after orthotopic lung transplantation. Am J Gastroenterol 1996; 91 (11) 2382-2390
• 332 Benden C, Aurora P, Curry J, Whitmore P, Priestley L, Elliott MJ. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol 2005; 40 (1) 68-71
• 333 Subhi R, Ooi R, Finlayson F , et al. Distal intestinal obstruction syndrome in cystic fibrosis: presentation, outcome and management in a tertiary hospital (2007-2012). ANZ J Surg 2014; 84 (10) 740-744
• 334 Farrelly PJ, Charlesworth C, Lee S, Southern KW, Baillie CT. Gastrointestinal surgery in cystic fibrosis: a 20-year review. J Pediatr Surg 2014; 49 (2) 280-283
• 335 Parisi GF, Di Dio G, Franzonello C , et al. Liver disease in cystic fibrosis: an update. Hepat Mon 2013; 13 (8) e11215
• 336 Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 2010; 24 (5) 585-592
• 337 Bhardwaj S, Canlas K, Kahi C , et al. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol 2009; 43 (9) 858-864
• 338 Pokorny CS, Bye PT, MacLeod C, Selby WS. Antibiotic-associated colitis and cystic fibrosis. Dig Dis Sci 1992; 37 (9) 1464-1468
• 339 Rivlin J, Lerner A, Augarten A, Wilschanski M, Kerem E, Ephros MA. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr 1998; 132 (1) 177-179
• 340 Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile—Associated diarrhea: A review. Arch Intern Med 2001; 161 (4) 525-533
• 341 Lee JT, Hertz MI, Dunitz JM , et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant 2013; 27 (2) 303-310
• 342 Nagakumar P. Pseudomembranous colitis in cystic fibrosis. Paediatr Respir Rev 2013; 14 (Suppl. 01) 26-27
• 343 Yates B, Murphy DM, Fisher AJ , et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. BMJ Case Rep 2009; 2009: xx
• 344 Madill J, Gutierrez C, Grossman J , et al; Toronto Lung Transplant Program. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001; 20 (3) 288-296
• 345 Singer LG, Brazelton TR, Doyle RL, Morris RE, Theodore J ; International Lung Transplant Database Study Group. Weight gain after lung transplantation. J Heart Lung Transplant 2003; 22 (8) 894-902
• 346 Hollander FM, van Pierre DD, de Roos NM, van de Graaf EA, Iestra JA. Effects of nutritional status and dietetic interventions on survival in Cystic Fibrosis patients before and after lung transplantation. J Cyst Fibros 2014; 13 (2) 212-218
• 347 Armitage JM, Kormos RL, Stuart RS , et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10 (6) 877-886 , discussion 886–887
• 348 Randhawa PS, Jaffe R, Demetris AJ , et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327 (24) 1710-1714
• 349 Cohen AH, Sweet SC, Mendeloff E , et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000; 161 (4, Pt 1): 1252-1255
• 350 Aris RM, Maia DM, Neuringer IP , et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996; 154 (6, Pt 1): 1712-1717
• 351 Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J 2004; 23 (2) 334-342
• 352 Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell III PW, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95 (5) 381-387
• 353 Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105 (2) 122-129
• 354 Schöni MH, Maisonneuve P, Schöni-Affolter F, Lowenfels AB ; CF/CSG Group. Cancer risk in patients with cystic fibrosis: the European data. J R Soc Med 1996; 89 (Suppl. 27) 38-43
• 355 Rousseau A, Monchaud C, Debord J , et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25 (1) 28-35
• 356 Knoop C, Vervier I, Thiry P , et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003; 76 (4) 683-688
• 357 Brugière O, Thabut G, Castier Y , et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest 2003; 123 (6) 1832-1837
• 358 Aigner C, Jaksch P, Taghavi S , et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27 (1) 60-65
• 359 Kawut SM, Lederer DJ, Keshavjee S , et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177 (1) 114-120